Paul Mampilly Sees The Next Big Stock To Invest In

Posted on January 27, 2018 By

At Banyan Hill Publishing stock picking professional Paul Mampilly publishes Profits Unlimited. This is a newsletter that costs $97 a year and is published every month. Each month he highlights a company that he thinks is going to be a great investment going forward. One of his ads about Profits Unlimited talks about a healthcare company that he thinks is going to revolutionize precision medicine. This ad was released in July 2017.

When talking about this healthcare company Paul Mampilly says that this company is about to release what amounts to the greatest medical breakthrough ever recorded. He says it’s more important than any vaccine or drug that has been developed and will change how the industry approaches treating diseases.

Before revealing the company Paul Mampilly spills some details while still being rather vague. He says the company is located in the mid-West, for example. He also says that it’s a company worth $1.5 billion presently. Other hints are that it was founded at the beginning of the 1990s and the chief executive officer has been in the industry for 25 years. He says that the company has developed a DNA sequencing technique that will enable doctors to determine whether their patients will develop a disease and how it can best be treated.

All indications are that the company he is pointing at is Myriad Genetics, based in Salt Lake City, Utah. This is a company that is based on providing personalized medicine including DNA sequencing services. They’re mainly focused on cancer but they are developing tests for other types of diseases as well.

When Paul Mampilly started recommending that his readers invest in Myriad Genetics stock was worth around $25 a share. Back in the summer quarter, its value as a company was $1.5 billion. It is now valued at $2.2 billion. It looks like his readers who took his advice have made a pretty good profit.

Paul Mampilly used to trade on Wall Street. He got tired of that lifestyle, though, so he retired and moved his family out of New York City. He now helps average investors know what stocks to invest in based on his research. He also provides consulting services through his company, Capuchin Consulting, headquartered in Durham, North Carolina. In the past he had worked for companies like Deutsche Asset Management and ING Funds. For Kinetics Asset Management he managed their hedge fund for over five years.

Paul Mampilly’s Facebook Page: